A Smarter Breathing Machine That Didn't Change the Results: Two Ways of Helping Premature Babies Breathe

What a 2025 review of five clinical trials found when it compared a diaphragm-guided breathing support with standard nasal CPAP

When a baby is born too early, the lungs are often the last organs ready for the outside world, and helping that baby breathe without putting a tube down the windpipe is one of the central goals of newborn intensive care. A 2025 research review compared two gentle, tube-free breathing methods — a widely used one called nasal CPAP and a newer, "smarter" one called NIV-NAVA that follows the baby's own diaphragm — and found that, across every outcome measured, the two worked about equally well [1]. That is a genuinely useful finding for families, and this article explains what these methods are, why the comparison matters, and what the result does and does not mean for a premature baby's care.

Why breathing support is such a delicate balance for premature babies

Premature lungs are fragile and not yet finished growing. Decades ago, the standard response to a struggling newborn was to place a breathing tube into the windpipe and connect a ventilator. That approach saves lives, but doctors gradually learned that the pressure and mechanics of a ventilator can also injure these delicate lungs, and that this injury is one of the main causes of a chronic lung condition of prematurity called bronchopulmonary dysplasia, or BPD [2]. The goal shifted: keep the breathing tube out whenever it is safe to do so, and support the baby from the outside, through the nose, instead.

The most common way to do that is nasal CPAP — continuous positive airway pressure. It works by delivering a steady, gentle cushion of air pressure through small prongs or a mask in the baby's nose, which keeps the tiny air sacs in the lungs from collapsing between breaths. CPAP is familiar to every NICU team, it is comparatively simple, and studies show that starting it early, rather than reaching first for a breathing tube, lowers the combined risk of death or BPD in very premature babies [3]. It became the foundation of modern gentle breathing support.

But CPAP is not perfect. A steady pressure does not actively help the baby take each breath, and a meaningful share of very premature babies on CPAP still end up needing a breathing tube because they retain too much carbon dioxide or cannot keep their oxygen up. That gap is what has driven doctors to invent and test more sophisticated methods.

The idea behind the "smarter" machine

One such method is NIV-NAVA, which stands for non-invasive neurally adjusted ventilatory assist. Its central idea is elegant. Every breath a baby takes begins with an electrical signal traveling to the diaphragm, the main breathing muscle beneath the lungs. NIV-NAVA uses a soft feeding tube fitted with tiny sensors that detect that electrical signal, and it delivers a puff of breathing support at the exact moment the baby is trying to inhale, sized to how hard the baby is working. In principle, this keeps the machine and the baby perfectly in step.

That matters because the older tube-free methods have a recurring problem called asynchrony — the baby and the machine breathing out of time with each other. With the usual methods, air leaks around the nasal prongs and the baby's own breathing rhythm is irregular, so many machine-delivered puffs arrive at the wrong moment. In-between methods such as nasal intermittent positive pressure ventilation (NIPPV), which adds gentle extra puffs on top of CPAP [4], especially to help babies after a breathing tube is removed [5], and high-flow nasal cannula, a softer interface many babies tolerate well [6], were each developed to do better than plain CPAP. NIV-NAVA promised to go a step further by syncing to the baby's own nerve signals — an approach doctors classify separately as diaphragm-triggered support [7]. The obvious question — does that clever synchronization actually lead to better results for the baby? — is what researchers set out to answer.

How the researchers studied the question

The research was led by a team at Guangzhou Women and Children's Medical Center in China. Rather than run a single new trial, they did a systematic review and meta-analysis, which means they searched the world's medical literature — six databases, including Chinese-language ones — to find every high-quality randomized trial that had directly compared NIV-NAVA against nasal CPAP in premature babies, then carefully combined those trials' results into one bigger picture [1]. A randomized trial is one in which babies are assigned to one method or the other by chance, which is the fairest way to tell whether a treatment truly makes a difference. An earlier, smaller review in 2022 had asked the same question but had too little data to give a clear answer [8].

They found five such trials, together involving 326 premature babies — 161 supported with NIV-NAVA and 165 with nasal CPAP. The babies were born between about 28 and 37 weeks of pregnancy (a full-term pregnancy is around 40 weeks), and the trials were carried out in China, South Korea, Brazil, and Finland between 2012 and 2019. In three of the trials, the method was used as the baby's first breathing support; in two, it was used to help babies stay stable after a breathing tube was removed.

What they found: a tie, on every measure

The result was consistent and clear: NIV-NAVA and nasal CPAP performed about the same on everything the researchers measured. Babies on the smarter machine were no less likely to end up needing a breathing tube — the outcome that matters most — and no less likely to need surfactant, a medicine that helps open the lungs. On the safety side, rates of chronic lung disease (BPD) were slightly lower with NIV-NAVA but not by enough to be a real difference rather than chance; rates of a serious bowel problem called necrotizing enterocolitis were identical; and rates of a collapsed lung (pneumothorax) did not differ either. In plain terms, the clever, diaphragm-guided approach did not beat the simpler steady-pressure approach on any outcome the trials tracked [1].

It is worth being precise about what "no difference" means here. It does not prove the two methods are exactly equal. Because only five small trials existed, the combined study was not large enough to detect small differences that might still matter. The slightly lower chronic-lung-disease numbers with NIV-NAVA, for example, hint at a possible benefit that a bigger, more definitive trial might one day confirm — or might not. What the review can say with confidence is that there is currently no evidence that NIV-NAVA produces better results than good old-fashioned CPAP, and also no evidence that it is less safe.

What this means for families and their baby's care

If your baby is receiving breathing support in the NICU, the most reassuring takeaway is this: whether the team uses nasal CPAP or NIV-NAVA, the best available evidence says your baby's outcomes are likely to be similar. CPAP is not an inferior or outdated choice; it is a well-proven foundation of care that this new comparison did not manage to beat. Broader studies that line up all the tube-free methods against one another, both for first-line support and for use after a breathing tube is removed, have so far failed to crown a clear winner [9][10]; even a carefully run three-way trial found only small differences between methods [11], and much of the benefit of gentle support has historically come from pairing it with surfactant medicine rather than from the machine itself [12]. And NIV-NAVA is not an unsafe experiment; it is a promising method that simply has not yet proven itself superior.

Which method a particular unit uses often comes down to practical factors rather than one being clearly better. NIV-NAVA needs a specific type of ventilator, a special sensing tube that has to be placed and maintained carefully, and staff trained to read the diaphragm signal. Some hospitals have all of that and use NIV-NAVA readily; others rely on CPAP and step up to NIPPV when needed, which is an entirely sound approach. If you are ever unsure why a particular method was chosen for your baby, it is completely reasonable to ask the team — and the honest answer will usually be that they are matching the method to how your baby is breathing and to the tools and expertise their unit has, not choosing between a good option and a bad one.

What researchers are working on next

The authors of the review are careful not to dismiss NIV-NAVA. Their conclusion is that it "has not obtained significant advantages" yet, but that it "is still a potential" method that deserves more study. The honest state of the science is that the trials done so far have been too few, too small, and too varied — and, because you cannot hide from staff which breathing machine a baby is on, harder to run without bias than a typical drug trial. What the field needs now is larger studies carried out across many hospitals, designed to measure the outcomes that matter most to families and clinicians, and able to tell apart the two situations where these machines are used — helping a baby breathe from the start versus keeping a baby stable after a tube is removed.

Until those studies are done, careful, flexible bedside judgment remains the guiding principle, and both methods will continue to have a place. Families interested in how doctors weigh other gentle breathing methods against one another may find In[Neo]Sight's related plain-language articles helpful, including one on comparing nasal high-frequency oscillation with NIPPV after a breathing tube is removed and one on high-flow nasal cannula versus a gentle NIPPV interface. The broader message across all of them is encouraging: newborn medicine now has several safe, effective, tube-free ways to help premature lungs, and researchers keep testing them rigorously so that families can trust that the method chosen for their baby is grounded in real evidence.

References

  1. Yuan Y, He F, Wu D, Zou H. Non-invasive neurally adjusted ventilatory assist versus nasal continuous positive airway pressure for premature infants: a systematic review and meta-analysis. Eur J Med Res. 2025;30:577. doi:10.1186/s40001-025-02803-0 ↩
  2. Brown MK, DiBlasi RM. Mechanical ventilation of the premature neonate. Respir Care. 2011;56(9):1298–1311. doi:10.4187/respcare.01429 ↩
  3. Subramaniam P, Ho JJ, Davis PG. Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants. Cochrane Database Syst Rev. 2016;6:CD001243. doi:10.1002/14651858.CD001243.pub3 ↩
  4. Rüegger CM, Owen LS, Davis PG. Nasal intermittent positive pressure ventilation for neonatal respiratory distress syndrome. Clin Perinatol. 2021;48(4):725–744. doi:10.1016/j.clp.2021.07.004 ↩
  5. Lemyre B, Davis PG, De Paoli AG, Kirpalani H. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev. 2017;2(2):CD003212. doi:10.1002/14651858.CD003212.pub3 ↩
  6. Manley BJ, Owen LS, Doyle LW, et al. High-flow nasal cannulae in very preterm infants after extubation. N Engl J Med. 2013;369(15):1425–1433. doi:10.1056/NEJMoa1300071 ↩
  7. Goel D, Oei JL, Smyth J, Schindler T. Diaphragm-triggered non-invasive respiratory support in preterm infants. Cochrane Database Syst Rev. 2020;3(3):CD012935. doi:10.1002/14651858.CD012935.pub2 ↩
  8. Xu Y, Zhu X, Kong X, Li J. Outcomes of noninvasive neurally adjusted ventilatory assist and nasal continuous positive airway pressure in preterm infants: a systematic review and meta-analysis. Arch Argent Pediatr. 2022;120(2):89–98. doi:10.5546/aap.2022.eng.89 ↩
  9. Ramaswamy VV, More K, Roehr CC, Bandiya P, Nangia S. Efficacy of noninvasive respiratory support modes for primary respiratory support in preterm neonates with respiratory distress syndrome: systematic review and network meta-analysis. Pediatr Pulmonol. 2020;55(11):2940–2963. doi:10.1002/ppul.25011 ↩
  10. Ramaswamy VV, Bandyopadhyay T, Nanda D, et al. Efficacy of noninvasive respiratory support modes as postextubation respiratory support in preterm neonates: a systematic review and network meta-analysis. Pediatr Pulmonol. 2020;55(11):2924–2939. doi:10.1002/ppul.25007 ↩
  11. Zhu X, Qi H, Feng Z, Shi Y, De Luca D. Noninvasive high-frequency oscillatory ventilation vs nasal continuous positive airway pressure vs nasal intermittent positive pressure ventilation as postextubation support for preterm neonates in China: a randomized clinical trial. JAMA Pediatr. 2022;176(6):551–559. doi:10.1001/jamapediatrics.2022.0710 ↩
  12. Isayama T, Chai-Adisaksopha C, McDonald SD. Noninvasive ventilation with vs without early surfactant to prevent chronic lung disease in preterm infants: a systematic review and meta-analysis. JAMA Pediatr. 2015;169(8):731–739. doi:10.1001/jamapediatrics.2015.0510 ↩